While nausea, vomiting, and diarrhea are the most commonly reported gastrointestinal adverse effects with GLP-1-based therapies (occurring in 15-40% of patients depending on the agent and dose), FDA prescribing information for several of these medications does list dyspepsia (indigestion) and, in some cases, gastroesophageal reflux disease (GERD) as reported adverse reactions
The goal in coaching is to help you build a healthy, intentional relationship with food, regardless of how loud or quiet that background chatter is
How does the unique design of oral Semaglutide address the challenges of first-pass metabolism and bioavailability compared to injectable GLP-1 receptor agonists
Manufacturing companies evaluate additional factors unique to their programs
A single missed dose won't reverse your progress, but you may notice increased hunger and cravings for 23 days as medication levels drop
Why the Link Matters The connection between Ozempic and NAION carries more weight because the people prescribed the drug already face a higher risk for eye problems
